Acam2000 Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to smallpox eradication programs, biodefense initiatives, military vaccination needs, regulatory approvals, public health preparedness policies.

The growth in the forecast period can be attributed to renewed mpox outbreaks, increased biodefense funding, global health security focus, expansion of emergency stockpiles, government procurement programs. Major trends in the forecast period include strategic stockpiling of smallpox vaccines, preparedness for emerging orthopox threats, government controlled vaccine distribution, focus on high risk population immunization, national biosecurity programs.

The increasing prevalence of infectious diseases is expected to drive the growth of the ACAM2000 market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, or parasites, which can be transmitted directly or indirectly between individuals. The rising incidence of infectious diseases is fueled by increased global travel, which facilitates the rapid spread of pathogens across borders. ACAM2000 aids in managing infectious diseases by providing immunization against smallpox and mpox, reducing outbreak risks and strengthening public health preparedness. The vaccine supports healthcare systems and governments in mitigating the impact of potential bioterrorism threats and naturally occurring infections, ensuring rapid protection for high-risk populations and strategic stockpiles. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England rose to 4,850 in 2023, marking a 10.7% increase from 4,380 cases in 2022. Therefore, the growing prevalence of infectious diseases is contributing to the expansion of the ACAM2000 market.

Rising healthcare expenditure is also expected to propel the growth of the ACAM2000 market. Healthcare expenditure, which includes spending on personal healthcare, preventive services, and public health programs, is increasing due to aging populations, chronic diseases, advanced medical technologies, high drug prices, and growing demand for services. Funding from healthcare expenditure supports ACAM2000 through procurement, stockpiling, distribution, and administration as part of biodefense and public health preparedness initiatives. For instance, in May 2024, the UK Office for National Statistics reported that total healthcare spending rose by 5.6% in nominal terms from 2022 to 2023, compared with 0.9% growth in 2022, while long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, rising healthcare expenditure is contributing to the growth of the ACAM2000 market.

Key companies in the ACAM2000 market are focusing on advancing their vaccine portfolios through the development of next-generation formulations to improve accessibility, enhance safety, and address public health threats. Next-generation vaccines refer to updated versions that may offer benefits such as longer shelf life, reduced dosage requirements, or refined manufacturing processes. For example, in August 2024, Emergent BioSolutions Inc., a U.S.-based biopharmaceutical company, received FDA approval for the supplemental Biologics License Application (sBLA) for ACAM2000 (Smallpox and Mpox [Vaccinia] Vaccine, Live), expanding its indication to include prevention of pox in high-risk individuals. This approval was supported by human safety data and evidence from controlled animal studies demonstrating the vaccine’s effectiveness against mpox virus exposure.

Major companies operating in the acam2000 market are Emergent BioSolutions Inc.

North America was the largest region in the acam2000 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acam2000 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acam2000 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the acam2000 market by increasing costs related to vaccine production materials and controlled distribution logistics. These effects are most evident in government and defense health programs across north america and europe. Higher import duties have influenced national stockpiling budgets. Procurement timelines have also been affected by regulatory clearance processes. At the same time, tariffs are encouraging domestic vaccine manufacturing and strengthening national biosecurity supply chains.

The acam2000 market research report is one of a series of new reports that provides acam2000 market statistics, including acam2000 industry global market size, regional shares, competitors with a acam2000 market share, detailed acam2000 market segments, market trends and opportunities, and any further data you may need to thrive in the acam2000 industry. This acam2000 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

ACAM2000 is a live vaccinia virus vaccine approved by the Food and Drug Administration for immunization against smallpox. It is primarily administered to individuals at high risk of exposure, including military personnel and laboratory workers handling orthopoxviruses. ACAM2000 works by introducing a weakened virus similar to smallpox, prompting the body to develop immunity against the disease.

The main indications for ACAM2000 are smallpox and mpox. Smallpox is a viral infection caused by the variola virus, eradicated globally through vaccination but still considered a bioterrorism concern. Vaccines like ACAM2000 are used to immunize high-risk individuals to ensure protection against potential outbreaks. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, with end users including adults and the geriatric population.

The acam2000 market consists of sales of diluent for reconstitution, bifurcated needles, sterile syringes, and emergency use authorization documentation. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.